ArticleInternational journal of clinical pharmacy2018
Pharmacovigilance in developing countries (part I): importance and challenges.
Article in International journal of clinical pharmacy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Adverse Drug Reaction Costs and Study Quality in Africa: A Systematic Review of Cost-of-Illness Studies.PharmacoEconomics - open · 2026Pooled it
- Pooled it
- A Systematic Review of Pharmacovigilance Systems in Developing Countries Using the WHO Pharmacovigilance Indicators.Therapeutic innovation & regulatory science · 2022Pooled it
- Risk of drug-related aggression in pediatric populations: a pharmacovigilance analysis using the FAERS database.Frontiers in pediatrics · 2026Article
- Safety reporting in neonatal clinical trials: reflections towards optimal, globally relevant approaches.Trials · 2025Article
- Building functional and sustainable pharmacovigilance systems: an analysis of pharmacovigilance development across high-, middle- and low-income countries.Therapeutic advances in drug safety · 2025Article
- Cardiovascular and Metabolic Adverse Events of Endocrine Therapies in Women with Breast Cancer: A Disproportionality Analysis of Reports in the FDA Adverse Event Reporting System.Cancer medicine · 2025Article
- An Exploratory Bibliometric Analysis of African Pharmacovigilance Research Output Using SCOPUS.Cureus · 2024Review
- The Role of ISoP in the Advancement of Pharmacovigilance in Low-and Middle-Income Countries (LMICs).Drug safety · 2023Article
- Article
- Exploring the association between selective serotonin reuptake inhibitors and rhabdomyolysis risk based on the FDA pharmacovigilance database.Scientific reports · 2023Article
- Adverse Events Following Immunizations in Infants Under 1 Year of Age in Lorestan Province, Western Iran.Journal of preventive medicine and public health = Yebang Uihakhoe chi · 2023Article
- Challenges and lessons learned from four years of planning and implementing pharmacovigilance enhancement in sub-Saharan Africa.BMC public health · 2022Article
- Prospective observational study to evaluate the clinical and biological safety profile of pyronaridine-artesunate in a rural health district in Burkina Faso.Pharmacology research & perspectives · 2022Observational
- A qualitative exploration of pharmacovigilance policy implementation in Jordan, Oman, and Kuwait using Matland's ambiguity-conflict model.Globalization and health · 2021Article
- Building a Sustainable Comprehensive Multiple Myeloma Program in Western Kenya.JCO global oncology · 2021Article
- Direct reporting of adverse drug reactions by healthcare consumers in Africa: a narrative review.International journal of clinical pharmacy · 2021Review
- [Knowledge and attitude about Pharmacovigilance practices of pharmacy professionals of community pharmacy and hospital pharmacy in Spain.]Revista espanola de salud publica · 2020Article
- Challenges to the consolidation of pharmacovigilance practices in Brazil: limitations of the hospital pharmacist.Therapeutic advances in drug safety · 2020Article
- Optimal Approach and Strategies to Strengthen Pharmacovigilance in Sub-Saharan Africa: A Cohort Study of Patients Treated with First-Line Artemisinin-Based Combination Therapies in the Nanoro Health and Demographic Surveillance System, Burkina Faso.Drug design, development and therapy · 2020Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The thalidomide disaster was the significant historical event that acted as a catalyst for pharmacovigilance activity. Following this event developed countries initiated drug monitoring systems that evolved and now extend their scope to broader drug-related safety issues; however, this was not the case in developing countries. Pharmacovigilance is still a relatively new concept with low priority in developing countries although various issues are raising concerns that magnify the need for systems to monitor post marketing drug safety in these countries. This article analyzes the barriers to introducing robust pharmacovigilance systems in developing countries.
Indexed as
Identifiers
29248988What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.